0O8G Stock Chart & Stats
€3.02
€0.00(0.00%)
At close: 4:00 PM EDT
€3.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.02 - €3.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.44M
Enterprise Value€107.73M
Total Cash (Recent Filing)€19.21M
Total Debt (Recent Filing)€105.85M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding95,417,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.67Price Target Upside-77.83% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€99.89M
Bulls Say, Bears Say
Bulls Say
Revenue ScalingThe substantial multi-year revenue increase indicates expanding adoption of MDxHealth’s diagnostic portfolio and a broader commercial base. Maintaining gross margins near 60% provides economic support for continued investment in sales, clinical evidence, and product development as the company scales.
Clinical Evidence And Product DevelopmentPeer-reviewed clinical evidence can strengthen physician confidence and support the utility of MDxHealth’s tests in prostate-cancer decisions. Continued AI and research initiatives may broaden the platform’s clinical relevance and reinforce differentiation over the next several quarters.
Operational Focus And Liability ReductionExiting Resolve and closing the Plano lab concentrate resources on the core prostate-cancer franchise while removing a material contingent liability. This streamlining can reduce operational complexity and improve management focus, even though execution and profitability benefits still need to emerge.
Bears Say
Sales-Force DisruptionSales-force turnover after the Resolve discontinuation disrupted execution and caused third-quarter revenue to miss internal expectations. Guidance suspension reduces visibility into near-term demand conversion, while weaker tissue volumes show that the commercial reset has not yet stabilized.
Persistent Losses And Going-Concern RiskLarge continuing losses and a growing accumulated deficit demonstrate that revenue growth has not yet translated into self-sustaining profitability. The stated going-concern uncertainty raises the importance of successful integration, operating improvement, and continued access to capital.
Leverage And Negative EquityHigher debt combined with negative equity materially weakens financial flexibility and increases dependence on successful operating improvement or external financing. This capital-structure strain can constrain investment choices and heighten refinancing or dilution risk over the medium term.
MDxHealth News
0O8G FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest share price was €3.02 and its highest was €3.02 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is €15.44M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 12 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -€0.16 earnings per share for the quarter, beating the consensus estimate of -€0.172 by €0.012.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Overvalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.08.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -€0.16 in its last earnings report, beating expectations of -€0.172. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in GB:0O8G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
0O8G Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all GB:0O8G earnings summaries0O8G Stock 12 Month Forecast
Average Price Target
€0.67
▼(-77.83% Downside)